United States: Daily Stock Market Performance Insight - January 22, 2026

Market indices showed positive momentum today, mirroring gains in U.S. markets. The Nasdaq Composite rose 0.91% to 23,436.02, the Russell 2000 increased 0.64% to 2,715.52, the Dow Jones Industrial Average climbed 0.63% to 49,384.01, and the S&P 500 increased 0.55% to 6,913.35. The Cboe Volatility Index (VIX) decreased by 7.22% to 15.68, indicating reduced market anxiety.

A key theme is the divergence in corporate earnings. GE Aerospace beat expectations with Q4 revenue of $12.72 billion and adjusted EPS of $1.57, forecasting 2026 revenue growth in the low double digits and adjusted EPS between $7.10 and $7.40, exceeding the $7.12 analyst forecast. However, Procter & Gamble missed sales estimates at $22.2 billion versus an expected $22.3 billion, and Intel shares plummeted 6.38% to $50.85 after a disappointing forecast due to manufacturing issues. This highlights selective strength within the earnings season.

Positive economic data provided further support. The Q3 2025 GDP was revised upward to an annual rate of 4.4%, and corporate profits increased by $175.6 billion, an upward revision of $9.5 billion. Interactive Brokers also reported strong financials, with Net Interest Income surging 21% year-over-year to $967 million, benefiting from elevated interest rates and growing client cash balances reaching $150 billion. Defense spending also saw a significant increase, with contract obligations rising 9.3% to a record $521 billion in fiscal year 2025.

Alphabet received an upgrade to “strong buy” from Raymond James, resulting in a 1.8% increase in early trading, while Moderna continued its rally, climbing another 4% following a nearly 16% gain yesterday due to positive cancer vaccine data. These gains suggest continued investor interest in the technology and healthcare sectors.

Investors should watch for continued earnings reports and economic data releases. The contrast between GE Aerospace’s strong outlook and Intel’s struggles suggests a need for selective stock picking. The upward revision of GDP and strong corporate profit growth are positive signals, but the miss by Procter & Gamble indicates potential headwinds for consumer staples. Momentum remains in technology and healthcare, particularly with Alphabet and Moderna.